Go Pro
→ Central banks bought 710 tonnes - this fund pays monthly (From Investors Alley) (Ad)tc pixel Free VRAYQ Stock Alerts

ViewRay (VRAYQ) Competitors

Compare

VRAYQ vs. SDCCQ, GMVDF, TTOO, AFIB, and UTRS

Should you buy ViewRay stock or one of its competitors? ViewRay's main competitors and comparable companies include SmileDirectClub (SDCCQ), G Medical Innovations (GMVDF), T2 Biosystems (TTOO), Acutus Medical (AFIB), and Minerva Surgical (UTRS). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "healthcare equipment" industry.

How does ViewRay compare to SmileDirectClub?

ViewRay (NASDAQ:VRAYQ) and SmileDirectClub (NASDAQ:SDCCQ) are both small-cap healthcare companies, but which is the better stock? We will contrast the two businesses based on the strength of their profitability, media sentiment, valuation, earnings, dividends, risk, analyst recommendations and institutional ownership.

SmileDirectClub has higher revenue and earnings than ViewRay.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
ViewRay$102.21M0.00-$107.33MN/AN/A
SmileDirectClub$470.74M0.00-$86.40M-$0.13N/A

In the previous week, ViewRay's average media sentiment score of 0.00 equaled SmileDirectClub'saverage media sentiment score.

Company Overall Sentiment
ViewRay Neutral
SmileDirectClub Neutral

ViewRay has a beta of 0.77, meaning that its share price is 23% less volatile than the broader market. Comparatively, SmileDirectClub has a beta of 1.31, meaning that its share price is 31% more volatile than the broader market.

15.5% of ViewRay shares are owned by institutional investors. Comparatively, 0.1% of SmileDirectClub shares are owned by institutional investors. 2.5% of ViewRay shares are owned by insiders. Comparatively, 64.7% of SmileDirectClub shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Company Net Margins Return on Equity Return on Assets
ViewRayN/A N/A N/A
SmileDirectClub N/A N/A N/A

Summary

SmileDirectClub beats ViewRay on 4 of the 6 factors compared between the two stocks.

How does ViewRay compare to G Medical Innovations?

ViewRay (NASDAQ:VRAYQ) and G Medical Innovations (NASDAQ:GMVDF) are both small-cap healthcare companies, but which is the superior business? We will contrast the two businesses based on the strength of their analyst recommendations, profitability, risk, institutional ownership, valuation, dividends, media sentiment and earnings.

In the previous week, ViewRay's average media sentiment score of 0.00 equaled G Medical Innovations'average media sentiment score.

Company Overall Sentiment
ViewRay Neutral
G Medical Innovations Neutral

ViewRay has a beta of 0.77, suggesting that its share price is 23% less volatile than the broader market. Comparatively, G Medical Innovations has a beta of 29.41, suggesting that its share price is 2,841% more volatile than the broader market.

Company Net Margins Return on Equity Return on Assets
ViewRayN/A N/A N/A
G Medical Innovations N/A N/A N/A

G Medical Innovations has lower revenue, but higher earnings than ViewRay.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
ViewRay$102.21M0.00-$107.33MN/AN/A
G Medical Innovations$4.42M0.01-$24.63MN/AN/A

15.5% of ViewRay shares are held by institutional investors. Comparatively, 6.0% of G Medical Innovations shares are held by institutional investors. 2.5% of ViewRay shares are held by company insiders. Comparatively, 37.1% of G Medical Innovations shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Summary

G Medical Innovations beats ViewRay on 3 of the 5 factors compared between the two stocks.

How does ViewRay compare to T2 Biosystems?

ViewRay (NASDAQ:VRAYQ) and T2 Biosystems (NASDAQ:TTOO) are both small-cap healthcare companies, but which is the better investment? We will compare the two businesses based on the strength of their analyst recommendations, earnings, risk, dividends, media sentiment, profitability, institutional ownership and valuation.

ViewRay has a beta of 0.77, indicating that its stock price is 23% less volatile than the broader market. Comparatively, T2 Biosystems has a beta of 7.75, indicating that its stock price is 675% more volatile than the broader market.

In the previous week, ViewRay's average media sentiment score of 0.00 equaled T2 Biosystems'average media sentiment score.

Company Overall Sentiment
ViewRay Neutral
T2 Biosystems Neutral

15.5% of ViewRay shares are owned by institutional investors. Comparatively, 23.2% of T2 Biosystems shares are owned by institutional investors. 2.5% of ViewRay shares are owned by insiders. Comparatively, 0.0% of T2 Biosystems shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

T2 Biosystems has lower revenue, but higher earnings than ViewRay.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
ViewRay$102.21M0.00-$107.33MN/AN/A
T2 Biosystems$7.68M0.00-$50.08M-$3.89N/A

ViewRay has a net margin of 0.00% compared to T2 Biosystems' net margin of -563.16%.

Company Net Margins Return on Equity Return on Assets
ViewRayN/A N/A N/A
T2 Biosystems -563.16%N/A -174.06%

Summary

ViewRay and T2 Biosystems tied by winning 4 of the 8 factors compared between the two stocks.

How does ViewRay compare to Acutus Medical?

Acutus Medical (NASDAQ:AFIB) and ViewRay (NASDAQ:VRAYQ) are both small-cap healthcare companies, but which is the better business? We will compare the two businesses based on the strength of their earnings, media sentiment, profitability, dividends, analyst recommendations, risk, valuation and institutional ownership.

ViewRay has a net margin of 0.00% compared to Acutus Medical's net margin of -272.74%. ViewRay's return on equity of 0.00% beat Acutus Medical's return on equity.

Company Net Margins Return on Equity Return on Assets
Acutus Medical-272.74% -311.64% -11.57%
ViewRay N/A N/A N/A

In the previous week, Acutus Medical's average media sentiment score of 0.00 equaled ViewRay'saverage media sentiment score.

Company Overall Sentiment
Acutus Medical Neutral
ViewRay Neutral

56.9% of Acutus Medical shares are owned by institutional investors. Comparatively, 15.5% of ViewRay shares are owned by institutional investors. 5.2% of Acutus Medical shares are owned by insiders. Comparatively, 2.5% of ViewRay shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Acutus Medical has a beta of 5.7, suggesting that its stock price is 470% more volatile than the broader market. Comparatively, ViewRay has a beta of 0.77, suggesting that its stock price is 23% less volatile than the broader market.

Acutus Medical has higher earnings, but lower revenue than ViewRay.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Acutus Medical$7.16M0.00-$81.66M-$0.11N/A
ViewRay$102.21M0.00-$107.33MN/AN/A

Summary

ViewRay beats Acutus Medical on 5 of the 9 factors compared between the two stocks.

How does ViewRay compare to Minerva Surgical?

ViewRay (NASDAQ:VRAYQ) and Minerva Surgical (NASDAQ:UTRS) are both small-cap healthcare companies, but which is the superior investment? We will contrast the two businesses based on the strength of their dividends, risk, analyst recommendations, earnings, profitability, media sentiment, institutional ownership and valuation.

15.5% of ViewRay shares are owned by institutional investors. 2.5% of ViewRay shares are owned by company insiders. Comparatively, 8.5% of Minerva Surgical shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Company Net Margins Return on Equity Return on Assets
ViewRayN/A N/A N/A
Minerva Surgical N/A N/A N/A

Minerva Surgical has lower revenue, but higher earnings than ViewRay.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
ViewRay$102.21M0.00-$107.33MN/AN/A
Minerva Surgical$51.69M0.00-$34.11M-$1.81N/A

In the previous week, ViewRay's average media sentiment score of 0.00 equaled Minerva Surgical'saverage media sentiment score.

Company Overall Sentiment
ViewRay Neutral
Minerva Surgical Neutral

ViewRay has a beta of 0.77, indicating that its stock price is 23% less volatile than the broader market. Comparatively, Minerva Surgical has a beta of 2.41, indicating that its stock price is 141% more volatile than the broader market.

Summary

Minerva Surgical beats ViewRay on 4 of the 6 factors compared between the two stocks.

Get ViewRay News Delivered to You Automatically

Sign up to receive the latest news and ratings for VRAYQ and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding VRAYQ and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

VRAYQ vs. The Competition

Export
MetricViewRayHealthcare Equipment & Supplies IndustryHealthcare SectorNASDAQ Exchange
Market Cap$16K$5.95B$7.06B$13.10B
Dividend YieldN/A1.76%2.57%10.45%
P/E Ratio0.0026.22269.0625.28
Price / SalesN/A63.24592.9687.71
Price / CashN/A33.9270.4850.90
Price / BookN/A6.1012.916.24
Net Income-$107.33M$148.67M$3.45B$347.60M

ViewRay Competitors List

Export
CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
VRAYQ
ViewRay
N/AN/AN/AN/A$16K$102.21MN/A300
SDCCQ
SmileDirectClub
N/A$0.00
+∞		N/AN/A$40K$470.74MN/A2,700
GMVDF
G Medical Innovations
N/A$0.00
flat		N/AN/A$26K$4.42MN/A72
TTOO
T2 Biosystems
N/A$0.00
+100.0%		N/A-95.5%$21K$7.68MN/A180
AFIB
Acutus Medical
N/A$0.00
-50.0%		N/A-80.0%$3K$7.16MN/A340

Related Companies and Tools

Related Companies
Top 10 Stock Comparisons

This page (NASDAQ:VRAYQ) was last updated on 8/14/2026 by MarketBeat.com Staff.
From Our Partners
Here’s the stock symbol I’ve promised
Whitney Tilson of Stansberry Research has long recommended Berkshire Hathaway as a core retirement holding - b...
Stansberry Research | Sponsoredtc pixel
Trump’s New Currency Reset
Trump is launching a new $250 bill - but that may be a distraction. Behind the scenes, Executive Order 14241 i...
Porter & Company | Sponsoredtc pixel
Buy These Stocks Before August 31st
Keith Kaplan has invested $17 million into his own AI research platform, now used by 180,000 investors worldwi...
TradeSmith | Sponsoredtc pixel
Ray Dalio: Buy Gold. Get Paid.
Ray Dalio, founder of Bridgewater Associates, is urging investors to hold 15% of their portfolio in gold and c...
Investors Alley | Sponsoredtc pixel
Your book is inside
The "Sucker's Bet" Most New Options Traders Fall For Most people who try options lose money the same way. ...
Profits Run | Sponsoredtc pixel
CODE RED: AI Meltdown Imminent?
After correctly predicting the 2008 and 2020 stock market meltdowns, I believe this AI company is about to tri...
Paradigm Press | Sponsoredtc pixel
Gold buyout deals have handed shareholders overnight gains up to 79 percent
Gold major acquisitions have repriced junior miners overnight, with past deals delivering gains from 40% to 1,...
Golden Portfolio | Sponsoredtc pixel
Who Really Gets Rich from IPOs?
Peter Thiel turned a $500,000 stake in Meta into nearly $1 billion by investing eight years before its IPO. Tr...
Weiss Ratings | Sponsoredtc pixel